eligard 45 mg
recordati industria chimica e farmaceutica s.p.a. (3259649) - leuprorelinmonoacetat - pulver und lösungsmittel zur herstellung einer injektionslösung - teil 1 - pulver zur herstellung einer injektionslösung; leuprorelinmonoacetat (34837) 59,2 milligramm
eligard mensual 7,5 mg polvo y disolvente para solucion inyectable
recordati industria chimica e farmaceutica s.p.a. - leuprorelina acetato - polvo y disolvente para soluciÓn inyectable en jeringa precargada - 7,5 mg - leuprorelina acetato 7,5 mg - leuprorelina
eligard semestral 45 mg polvo y disolvente para solucion inyectable
recordati industria chimica e farmaceutica s.p.a. - leuprorelina acetato - polvo y disolvente para soluciÓn inyectable en jeringa precargada - 45 mg - leuprorelina acetato 45 mg - leuprorelina
eligard trimestral 22,5 mg polvo y disolvente para solucion inyectable
recordati industria chimica e farmaceutica s.p.a. - leuprorelina acetato - polvo y disolvente para soluciÓn inyectable en jeringa precargada - 22,5 mg - leuprorelina acetato 22,5 mg - leuprorelina
eligard 22.5 mg
kamada ltd, israel - leuprorelin acetate - powder and solvent for solution for injection - leuprorelin acetate 22.5 mg - eligard is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.
eligard 45 mg
kamada ltd, israel - leuprorelin acetate - powder and solvent for solution for injection - leuprorelin acetate 45 mg - eligard is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.
eligard 7.5 mg
kamada ltd, israel - leuprorelin acetate - powder and solvent for solution for injection - leuprorelin acetate 7.5 mg - eligard 7.5 mg is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer combination with radiotherapy.
eligard stungulyfsstofn og leysir, lausn 7,5 mg
recordati industria chimica e farmaceutica s.p.a.* - leuprorelinum acetat - stungulyfsstofn og leysir, lausn - 7,5 mg
eligard stungulyfsstofn og leysir, lausn 45 mg
recordati industria chimica e farmaceutica s.p.a.* - leuprorelinum acetat - stungulyfsstofn og leysir, lausn - 45 mg
eligard stungulyfsstofn og leysir, lausn 22,5 mg
recordati industria chimica e farmaceutica s.p.a.* - leuprorelinum acetat - stungulyfsstofn og leysir, lausn - 22,5 mg